This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen acción 0NQA
Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Elanix Biotechnologies AG
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.07 |
| 52 Week High | €0.07 |
| 52 Week Low | €0.07 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -96.41% |
| Change since IPO | -98.77% |
Noticias y actualizaciones recientes
No hay actualizaciones
Recent updates
No hay actualizaciones
Rentabilidad de los accionistas
| 0NQA | GB Biotechs | Mercado GB | |
|---|---|---|---|
| 7D | 0% | 1.1% | 1.2% |
| 1Y | n/a | -29.7% | -0.3% |
Rentabilidad frente al sector: Insufficient data to determine how 0NQA performed against the UK Biotechs industry.
Rentabilidad vs. Mercado: Insufficient data to determine how 0NQA performed against the UK Market.
Volatilidad de los precios
| 0NQA volatility | |
|---|---|
| 0NQA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Precio estable de las acciones: 0NQA has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine 0NQA's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | n/a | Lee-Ann Laurent-Applegate | www.elanixbiotechnologies.ch |
Resumen de fundamentos de Elanix Biotechnologies AG
| Estadísticas fundamentales de 0NQA | |
|---|---|
| Capitalización bursátil | €686.88k |
| Beneficios(TTM) | -€4.46m |
| Ingresos (TTM) | €280.19k |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está 0NQA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 0NQA | |
|---|---|
| Ingresos | €280.19k |
| Coste de los ingresos | €348.59k |
| Beneficio bruto | -€68.39k |
| Otros gastos | €4.39m |
| Beneficios | -€4.46m |
Últimos beneficios comunicados
Jun 30, 2018
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0.0% |
¿Cómo se ha desempeñado 0NQA a largo plazo?
Ver rendimiento histórico y comparativa